Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • UN panel challenges...

    UN panel challenges market based approach to drug RnD

    Written by savita thakur thakur Published On 2016-09-15T12:33:22+05:30  |  Updated On 15 Sept 2016 12:33 PM IST
    UN panel challenges market based approach to drug RnD

    London : The world cannot rely solely on free markets to deliver medicines needed by billions of people in poor countries, so governments should commit to a legally binding convention to coordinate and fund research and development.


    That's the conclusion of a major United Nations report, which is bound to stir fierce debate between supporters of the current market-based system of drug development and those favouring a greater role for the state.


    The high-level panel was set up last year by UN Secretary General Ban Ki moon to find solutions to the "policy incoherence" between the rights of inventors, international human rights law, trade rules and public health needs.


    The issue has been given added urgency by the recent Ebola and Zika outbreaks, two diseases centred on the developing world where there has been little commercial incentive to develop either vaccines or treatments.


    The final report, issued on Wednesday, calls for a de-linkage of R&D costs and drug prices at least in areas where the system is failing, such as tropical diseases and the hunt for new antibiotics against "super bug" resistant bacteria.


    It urges the UN Secretary General to start a process for governments to negotiate global agreements on the coordination, financing and development of priority research programmes.


    "This includes negotiations for a binding R&D Convention that delinks the costs of research and development from end prices to promote access to good health for all," the report said.


    The report attacks the "implicit threats" it says are sometimes used by Western governments and companies to stop poorer countries from exercising their right to over-ride drug patents under World Trade Organization rules.


    That may not go down well in Washington, given the United States' long standing defence of the international intellectual property system, which has governed world trade for more than two decades.


    The panel also calls for greater transparency on the true cost of developing a new drug, citing estimates of anything between $150 million and $4 billion per medicine. And it wants disclosure on the real prices paid by insurers and governments for drugs, after discounts.


    The UN panel consisted of representatives from government, academia, health activism and industry, under the leadership of Ruth Dreifuss and Festus Mogae, the former presidents of Switzerland and Botswana.


    Not all the panel's members agreed with all its conclusions.


    GlaxoSmithKline Chief Executive Andrew Witty, one of the panellists, expressed serious doubts about the proposed R&D Convention, given the difficulty of raising the very substantial funds that would be needed from governments to make it work.

    Andrew WittyantibioticsEbolaFestus MogaeGlaxoSmithKlineresistant bacteriaRuth DreifussUN PanelWorld Trade OrganizationZika
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok